David Mai

Living immunotherapies in the form of synthetically modified immune cells have demonstrated remarkable success against various late-stage and chemotherapy-resistant cancers. However, they are less effective in solid tumors, feasible in only a subset of patients, and expensive. David’s research seeks to improve the safety, function, and manufacturing of these therapies by investigating scalable methods to produce more durable immunotherapy products more robustly from patients. These goals have key implications in advancing therapeutic success and increasing the accessibility of these novel treatments to more patients.

David’s motivations in educational and health equity are grounded in his experience as a first-generation student raised in an urban setting filled with socioeconomic inequality. Through HPRS, he seeks to learn more about determinants of health across fields, and explore how engineering and technology may be used to lower barriers in health equity and policy.


[contact-form-7 id=”1684″ title=”Share This Opportunity”]